Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
A Double-Blind, Placebo-Controlled 16-Week Study of Neflamapimod in Dementia with Lewy Bodies
2019-001566-15Phase 2Completed
- Sponsor
- CervoMed
- Start
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in dementia with Lewy bodies (DLB) comparing Neflamapimod with Placebo (2 arms). Primary endpoint: Change in composite NTB score. Started Jul 2019; status: completed.
02
Drugs
neflamapimod
03
Conditions
dementia with Lewy bodies (DLB)
Beyond the preview
Go deeper on 2019-001566-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001566-15.